EUCTR2014-005489-31-FI进行中（未招募）1 期
A Long-Term, Safety and Maintenance of Efficacy Study of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy or Obstructive Sleep Apnea
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria:
- •All subjects must meet the following criteria to be enrolled in the study.
- •1. Subject meets one of the following:
- •a. Completed Study 14-002 or 14-003 (Group A)
- •b. Completed Study 14-004, 15-004, 15-005, ADX-N05 201 or ADX-N05 202 (Group B)
- •2. Subject is able, in the opinion of the investigator, to take JZP-110 for 40 weeks if continuing from 14-002 or 14-003 or for 52 weeks if the subject completed 14-004, 15-004, 15-005, ADX-N05 201 or ADX-N05 202, and is able to complete all tests and visits described in this protocol.
- •3. Usual nightly total sleep time of at least 6 hours.
- •4. Body mass index from 18 to <45 kg/m2.
- •5. Consent to use a medically acceptable method of contraception for at least 2 months prior to the first dose of study drug, throughout the entire study period, and for 30 days after the study is completed.
- •6. Willing and able to comply with the study design schedule and other requirements.
- •7. Willing and able to provide written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 547
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 53
排除标准
- •Exclusion Criteria:
- •Subjects who demonstrate any of the following will be excluded from the study.
- •1. Female subjects who are pregnant, nursing, or lactating.
- •2. Usual bedtime later than 1 AM (0100 hours).
- •3. Occupation requiring nighttime or variable shift work.
- •4. Experienced any serious adverse event (SAE) in a previous study that was deemed related to JZP-110 or experienced an AE in a previous study that might prevent him/her from safely participating in and completing the current study.
- •5. Any other clinically relevant medical, behavioral, or psychiatric disorder other than narcolepsy or OSA that is associated with excessive sleepiness.
- •6. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria.
- •7. Presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy or safety assessments, or the ability of the subject to complete the trial per the judgment of the Investigator.
- •8. History of bariatric surgery within the past year or a history of roux-en-y procedure.
- •9. Presence of renal impairment or calculated creatinine clearance <60 mL/min.
- •10. Clinically significant ECG abnormality in the opinion of the Investigator.
- •11. This criterion has been removed.
- •12. Presence of significant cardiovascular disease including but not limited to: myocardial infarction within the past year, unstable angina pectoris, symptomatic congestive heart failure (ACC / AHA stage C or D), revascularization procedures within the past year, ventricular cardiac arrhythmias requiring an automatic implantable cardioverter defibrillator (AICD) or medication therapy, uncontrolled hypertension, systolic blood pressure =155 mmHg or diastolic blood pressure =95 mmHg at screening or Baseline for Group B subjects according to protocol specifications; or any history of cardiovascular disease or any significant cardiovascular condition that in the investigator's opinion may jeopardize subject safety in the study.
- •13. Laboratory value(s) outside the laboratory reference range that are considered to be clinically significant by the Investigator (clinical chemistry, hematology, and urinalysis); NOTE: Screening labs may be repeated once.
- •14. Excessive caffeine use one week prior to the Baseline Visit or anticipated excessive use during the study defined as >600 mg/day of caffeine.
- •15. Use of a monoamine oxidase inhibitor (MAOI) in the past 14 days or five half-lives of the drug (whichever is longer) prior to the Baseline Visit, or plans to use an MAOI during the study.
- •16. Received an investigational drug other than JZP-110 in the past 30 days or five half-lives (whichever is longer) before the Baseline Visit, or plans to use an investigational drug (other than the study drug) during the study.
- •17. Current or past (within the past 2 years) diagnosis of a moderate or severe substance use disorder according to DSM-5 criteria.
- •18. Nicotine dependence that has an effect on sleep (e.g., a subject who routinely awakens at night to smoke).
- •19. Current, past (within the past 2 years), or seeking treatment for a substance related disorder.
- •20. Urine drug screen positive for an illicit drug of abuse (including cannabinoids) at screening or at any point throughout the duration of the study, except for a prescribed
研究者
相似试验
进行中（未招募）
1 期
A long term clinical trial undertaken around the world in adult patients to treat Excessive Sleepiness in Subjects with Narcolepsy or Obstructive Sleep ApneaTreatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apneato increase the ability to stay awake throughout the day.MedDRA version: 20.0Level: HLTClassification code 10028716Term: Narcolepsy and associated conditionsSystem Organ Class: 100000005197EUCTR2014-005489-31-DEJazz Pharmaceuticals Inc.600
进行中（未招募）
1 期
A long term clinical trial undertaken around the world in adult patients to treat Excessive Sleepiness in Subjects with Narcolepsy or Obstructive Sleep ApneaEUCTR2014-005489-31-NLJazz Pharmaceuticals Inc.600
已完成
3 期
A Long-Term, Safety and Maintenance of Efficacy Study of JZP110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy or Obstructive Sleep Apneaexcessive sleepinesssleep disorder10040998NL-OMON45139Jazz Pharmaceuticals Inc.15
进行中（未招募）
1 期
ong-term follow-up of safety and effectiveness of MDMA-assisted therapy for posttraumatic stress disorderpost-traumatic stress disorder (PTSD)EUCTR2021-005596-39-CZMAPS Europe B.V.37
进行中（未招募）
1 期
An extension study on Coversin for Patients with PNH and aHUS who received benefit from their initial studyParoxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS)MedDRA version: 21.1Level: PTClassification code 10018932Term: Haemolytic uraemic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 21.1Level: PTClassification code 10034042Term: Paroxysmal nocturnal haemoglobinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2016-004129-18-NLAkari Therapeutics Plc50